Morepen Labs Holds 41st AGM, Approves Dividend & Key Management Changes
Morepen Laboratories Limited conducted its 41st AGM on September 26, 2026. The meeting approved the financial statements for FY26 and a final dividend of ₹0.20 per share. Key decisions included changes in management designations and extending the timeline for hiving off the Medical Devices Business.
The AGM involved several key decisions including dividend approval, management re-appointments and role changes, and a significant corporate restructuring event (hiving off of Medical Devices Business). These are material events for the company and its shareholders.
The announcement details the proceedings of the Annual General Meeting, including routine approvals and management changes. While a dividend was approved, there are no significant positive or negative financial or strategic developments highlighted.
Morepen Laboratories Limited held its 41st Annual General Meeting (AGM) on Saturday, 26th September 2026, commencing at 1:00 p.m. IST, through Video Conferencing/Other Audio-Visual Means. The meeting was conducted in compliance with applicable regulations.
Key business transacted included the consideration and adoption of the audited financial statements, including consolidated financial statements, for the financial year ended 31st March 2026. Shareholders also approved the declaration of a final dividend of ₹0.20 per equity share of face value ₹2 each for the same financial year. The meeting also addressed the appointment of a director, the ratification of remuneration for Cost Auditors, the elevation of Mr. Sanjay Suri to Managing Director, the re-appointment of Mr. Sushil Suri as Chairman & Managing Director, and the extension of the approved timeline for hiving off the Medical Devices Business into its subsidiary, Morepen Medipath Limited.
The notice of the meeting, dated 4th August 2026, along with the Directors' and Auditors' reports for the financial year ended 31st March 2026, were presented. It was informed that there were no qualifications in the reports of the Statutory Auditors and Secretarial Auditors. Members had the opportunity to ask questions, which were addressed by the Chairman. Voting was conducted through remote e-voting and e-voting during the meeting, with Mr. Praveen Dua appointed as Scrutinizer. The meeting concluded at 2:15 p.m. IST. The company will separately intimate the voting results to the Stock Exchanges and publish them on its website.
What to do with a filing like this
Morepen Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Morepen Laboratories Limited. Read the original for the full detail.